Legacy’s CEO Jessica Scott, MD. JD, a founding member of the Bioethics Leadership Forum, joins distinguished leaders at Bioethics International’s 2025 Roundtable
Legacy Health Strategies is proud to spotlight CEO Jessica Scott’s continued leadership in advancing ethics, transparency, and patient centricity in the biopharmaceutical industry. On June 24, 2025, Scott participated in Bioethics International’s 16th Annual Pharmaceutical Executive Roundtable, co-hosted with EY, Yale’s Program for Biomedical Ethics, and Scientific American.
This year’s roundtable, titled “Ethics, Trust + Patient Centricity in Pharma: Defining Metrics for Success,” convened executives and thought leaders across the biopharmaceutical industry to shape meaningful, measurable standards for ethical conduct and patient-centered innovation in medicines development.
Topics ranged from:
- Transparency in global clinical research
- Demographic representation in clinical trials
- Improving access in low- and middle-income countries
- Aligning ESG efforts with ethical commitments
Dr. Scott has long been at the forefront of these movements. During her time at Takeda, she led the company to become the first pharmaceutical sponsor to contribute to Bioethics International. Previously, she represented GlaxoSmithKline when developing the industry benchmark, the Good Pharma Scorecard (GPS), that ranks pharma companies on their performance in ethics, trustworthiness, and patient engagement. That commitment to accountability continues through her leadership at Legacy Health, where she partners with biopharmaceutical organizations to bring the patient voice into every stage of research and development.
The 2025 Roundtable featured keynote remarks by former FDA Commissioners Dr. Robert Califf and Dr. Mark McClellan, as well as panels including leaders from the FDA, EMA, WHO, Bayer, Pfizer, Amgen, Takeda, BMS, Genentech and major patient advocacy organizations. This year’s collaborative conversations addressed the industry’s evolving role in improving clinical trial transparency, measuring demographic inclusion, and embedding patient perspectives into corporate strategy and public reporting.
“As an industry, we’re being called to not only talk about trust and transparency—but to prove it through meaningful metrics and public accountability,” said Scott. “Legacy is proud to help shape these standards and champion the patients at the center of every decision.”
The outcomes of this year’s roundtable are expected to inform future iterations of the Good Pharma Scorecard and influence global best practices in clinical research ethics and patient-centered innovation.
Learn more about the Roundtable and the Good Pharma Scorecard at bioethicsinternational.org
“As an industry, we’re being called to not only talk about trust and transparency—but to prove it through meaningful metrics and public accountability,” said Scott. “Legacy is proud to help shape these standards and champion the patients at the center of every decision.”
